《业绩》荣昌生物(09995.HK)全年亏损收窄至14.68亿人民币

阿斯达克财经
28 Feb

荣昌生物(09995.HK) 公布2024年度业绩快报,按中国会计准则,实现营业总收入17.15亿人民币(下同),按年增加58.4%,主要受惠注射用泰它西普和注射用维迪西妥单抗销量增加。亏损由上年度15.11亿元,收窄至14.68亿元,每股亏损2.73元。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-27 16:25。)

过往派息
公布日期派息事项派息内容
2024/10/29第三季业绩无派息
2024/08/16中期业绩无派息
2024/04/26第一季业绩无派息
2024/03/27末期业绩无派息

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10